Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B
Shots:
- Arbutus discontinues its P-Ia/Ib study of AB-506 due to disappointing clinical findings i.e- observation of two cases of acute hepatitis in P-Ia clinical study assessing Ab-506 in healthy volunteers for 28days
- Following the results of P-Ia/Ib study- Abratus drop its plan to initiate combination study of AB-506 and AB-729 in H2’20 and will present the results of P-Ia/Ib study in details regarding the two cases of acute hepatitis
- AB-506 is an oral HBV capsid inhibitor- being evaluated for the treatment of chronic hepatitis B while AB-729 is an RNA interference (RNAi) therapeutic targeted to hepatocytes utilizing Arbutus’ novel GalNAc delivery technology enabling SC administration with expected monthly dosing
Click here to read full press release/ article | Ref: Arbutus | Image: BC Technology
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
